Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug refers to a combination of **BMS-919373**, a highly functionalized quinazoline investigated as a selective and potent blocker of the voltage-gated potassium channel subunit Kv1.5 (IKur current), and **atorvastatin**, a widely used statin for the reduction of cholesterol and prevention of cardiovascular disease. BMS-919373 was developed for use in cardiovascular conditions such as atrial fibrillation, operating via selective blockade of Kv1.5 to modulate atrial electrophysiology[1]. Atorvastatin is a synthetic small molecule HMG-CoA reductase inhibitor (statin), which lowers cholesterol by inhibiting its biosynthesis and upregulates LDL receptor activity in the liver. The combination was studied pharmacokinetically in clinical trials to assess drug-drug interactions and potential combined effects on healthy subjects[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BMS-919373 + atorvastatin.